Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 220

1.

[Levosimendan treatment of severe acute congestive heart failure refractory to dobutamine/milrinone in children].

Prijić S, Rakić S, Nikolić L, Jovicić B, Stajević M, Vukomanović V, Kosutić J.

Vojnosanit Pregl. 2011 Nov;68(11):979-84. Serbian.

PMID:
22191317
2.
3.

The effects of levosimendan in cardiac surgery patients with poor left ventricular function.

De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ.

Anesth Analg. 2007 Apr;104(4):766-73. Erratum in: Anesth Analg. 2007 Jun;104(6):1544. Dosage error in article text.

PMID:
17377079
4.

[Efficacy and safety of intravenous levosimendan compared with dobutamine in decompensated heart failure].

Wang L, Cui L, Wei JP, Li GP, Qi GX, Hao YM, Wang WZ, Li HM, Liu J, Jiang DJ, Zhang YD.

Zhonghua Xin Xue Guan Bing Za Zhi. 2010 Jun;38(6):527-30. Chinese.

PMID:
21033135
5.

Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.

Follath F.

Ital Heart J. 2003 May;4 Suppl 2:34S-38S.

PMID:
14635368
6.

Levosimendan: a new inodilatory drug for the treatment of decompensated heart failure.

Kivikko M, Lehtonen L.

Curr Pharm Des. 2005;11(4):435-55. Review.

PMID:
15725064
7.

Pharmacologic treatment of heart failure due to ventricular dysfunction by myocardial stunning: potential role of levosimendan.

García González MJ, Domínguez Rodríguez A.

Am J Cardiovasc Drugs. 2006;6(2):69-75. Review.

PMID:
16555860
8.

Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone.

Barraud D, Faivre V, Damy T, Welschbillig S, Gayat E, Heymes C, Payen D, Shah AM, Mebazaa A.

Crit Care Med. 2007 May;35(5):1376-82.

PMID:
17414729
9.

Levosimendan: a review of its use in the management of acute decompensated heart failure.

Innes CA, Wagstaff AJ.

Drugs. 2003;63(23):2651-71. Review.

PMID:
14636085
10.

Early experience with Levosimendan in children with ventricular dysfunction.

Namachivayam P, Crossland DS, Butt WW, Shekerdemian LS.

Pediatr Crit Care Med. 2006 Sep;7(5):445-8. Erratum in: Pediatr Crit Care Med. 2007 Mar;8(2):197.

PMID:
16885788
11.

Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.

Earl GL, Fitzpatrick JT.

Ann Pharmacother. 2005 Nov;39(11):1888-96. Epub 2005 Oct 11. Review.

PMID:
16219899
12.

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L; Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study..

Lancet. 2002 Jul 20;360(9328):196-202.

PMID:
12133653
13.

Levosimendan versus dobutamine in heart failure patients treated chronically with carvedilol.

Duygu H, Turk U, Ozdogan O, Akyuz S, Kirilmaz B, Alioglu E, Gunduz R, Bozkaya YT, Turkoglu C, Payzin S.

Cardiovasc Ther. 2008 Fall;26(3):182-8. doi: 10.1111/j.1755-5922.2008.00050.x.

PMID:
18786088
14.

Usefulness of dobutamine-induced changes of the two-dimensional longitudinal deformation predict clinical and neurohumoral improvement in men after levosimendan treatment in acutely decompensated chronic heart failure.

Paraskevaidis IA, Bistola V, Ikonomidis I, Parissis JT, Papadopoulos C, Filippatos G, Kremastinos DT.

Am J Cardiol. 2008 Nov 1;102(9):1225-9. doi: 10.1016/j.amjcard.2008.06.060. Epub 2008 Sep 4.

PMID:
18940297
15.

Effects of levosimendan versus dobutamine on inflammatory and apoptotic pathways in acutely decompensated chronic heart failure.

Adamopoulos S, Parissis JT, Iliodromitis EK, Paraskevaidis I, Tsiapras D, Farmakis D, Karatzas D, Gheorghiade M, Filippatos GS, Kremastinos DT.

Am J Cardiol. 2006 Jul 1;98(1):102-6. Epub 2006 May 6.

PMID:
16784930
16.

Haemodynamic effects of levosimendan for low cardiac output after cardiac surgery: a case series.

Malliotakis P, Xenikakis T, Linardakis M, Hassoulas J.

Hellenic J Cardiol. 2007 Mar-Apr;48(2):80-8.

17.

[The effect of levosimendan and dobutamine treatment on QT dispersion in patients with decompensated heart failure: a prospective study].

Paksoy F, Ulaş T, Tursun I, Dal MS, Oztekin E, Borlu F.

Anadolu Kardiyol Derg. 2012 Feb;12(1):16-22. doi: 10.5152/akd.2012.004. Epub 2012 Jan 4. Turkish.

18.

Levosimendan: first in a new class of inodilator for acute and chronic severe heart failure.

Cleland JG, Nikitin N, McGowan J.

Expert Rev Cardiovasc Ther. 2004 Jan;2(1):9-19. Review.

PMID:
15038409
19.

Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.

Duygu H, Ozerkan F, Nalbantgil S, Zoghi M, Akilli A, Akin M, Nazli C, Ergene O.

Int J Cardiol. 2008 Jan 11;123(2):201-3. Epub 2007 Feb 20.

PMID:
17316845
20.

Levosimendan: beyond its simple inotropic effect in heart failure.

Antoniades C, Tousoulis D, Koumallos N, Marinou K, Stefanadis C.

Pharmacol Ther. 2007 May;114(2):184-97. Epub 2007 Feb 16. Review.

PMID:
17363065

Supplemental Content

Support Center